A ViiV Health care funded randomised trial comparing efficacy and safety of dolutegravir (DTG)-based antiretroviral therapy (ART) versus standard of care (SOC) among HIV-infected children less than18years of age (≥3kg) starting first line ART or switching to second line ART. This is an ongoing study that started in Jan 2017 and will end in May 2023. The ODYSSEY trial conducted at Baylor-Uganda contributed to the pharmacokinetic, safety and efficacy data that led to the FDA approval of dispersible dolutegravir tablets for use in children living with HIV for first-line and second line ART. This study is funded by ViiV health care, sponsored by PENTA Foundation and coordinated by Medical Research Council (MRC) clinical Trial Unit (CTU) at University College London (UCL). For more details follow the link: https://odysseytrial.org/